arrow
P

Primo N. Lara

University of California, Davis
H指数:72
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
2025-11-010
OA
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer

转录谱阐明了致死性前列腺癌中恩扎鲁他胺极端无反应的程序

2025-07-070
OAAI
POLE Mutation Associated With Microsatellite Instability and High Tumor Mutational Burden Confers Exquisite Sensitivity to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Case Report and Genomic Database Analysis

POLE突变与微卫星不稳定性和高肿瘤突变负荷相关,对非小细胞肺癌中免疫检查点抑制剂治疗的敏感性极高:病例报告和基因组数据库分析

2025-01-010
PRE
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216

体重指数与转移性激素敏感性前列腺癌患者总生存期的相关性:SWOG-1216患者层面数据分析

2024-11-010
PRE
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone- sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

3个月和7个月的前列腺特异性抗原水平可作为转移性激素敏感性前列腺癌总生存期的预后指标: SWOG S1216的结果,这是一项雄激素剥夺加Orteronel或比卡鲁胺的3期随机试验

2024-10-012
OA
Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis

II期随机双盲试验,评估阿昔替尼(Axi)联合或不含PF 04518600(一种OX40抗体,PFOX)在PD1/PDL1抗体(IO)疗法(Tx)后用于转移性肾细胞癌(mRCC)的最终分析。

2024-09-010
PRE
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
2024-09-013
PRE
A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
2024-07-251
OAAI
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel
2024-02-290
PRE
Kidney Cancer, Version 2.2024 Featured Updates to the NCCN Guidelines
2024-02-0123
PRE
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel
2024-02-016
OA
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

肾细胞癌术后辅助依维莫司 (EVEREST): 一项双盲、安慰剂对照、随机、3期试验

LANCET
IF88.5
2023-09-0121
OAAI